T cell receptor alpha variable 30Genealiases: TCRAV29S1 · TCRAV30S1
Q-omics provides the consensus-scored TRAV30 profile across patient tissues and cancer cell-line models. TRAV30 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, TRAV30 is differentially expressed in 7, with the highest sampling consensus in KICH. Additionally, TRAV30 RNA expression shows 14,351 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SKCM, KICH, and TGCT as cancer lineages where TRAV30 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAV30 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAV30 survival associations across molecular data types. TRAV30 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAV30 RNA expression–survival associations across cancer types. High TRAV30 expression shows unfavorable associations in UVM, ACC and COAD, but favorable associations in SKCM, HNSC and KIRC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for TRAV30 RNA expression.
This table summarizes TRAV30 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for TRAV30. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAV30 shows lower tumor expression in KICH, KIRP and LIHC and higher tumor expression in COAD, BRCA and KIRC. The KICH box plot shows higher TRAV30 RNA expression in normal versus tumor tissue (log2 FC = −3.318, t-test p < 0.001).
This table shows molecular features associated with TRAV30 in patient tissues and cancer cell lines. In patient samples, TRAV30 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
